Human respiratory syncytial virus (HRSV) is the most important viral cause of severe respiratory tract disease in infants. Two subgroups (A and B) have been identified, which cocirculate during, or alternate between, yearly epidemics and cause indistinguishable disease. Existing in vitro and in vivo models of HRSV focus almost exclusively on subgroup A viruses. Here, a recombinant (r) subgroup B virus (rHRSV B05 ) was generated based on a consensus genome sequence obtained directly from an unpassaged clinical specimen from a hospitalized infant. An additional transcription unit containing the gene encoding enhanced green fluorescent protein (EGFP) was introduced between the phosphoprotein and matrix genes (position 5) of the genome to generate rHRSV B05 EGFP(5).
H uman respiratory syncytial virus (HRSV) is the most important viral cause of respiratory tract disease in infants (1) . HRSV infections are observed during seasonal outbreaks in winter or during the rainy season in the tropics (2) . The virus usually causes a self-limiting upper respiratory tract (URT) infection, resulting in rhinorrhea and other common cold-like clinical signs (3) . However, in a minority of cases the infection can also spread to the lower respiratory tract (LRT), resulting in severe pneumonia or bronchiolitis. Risk factors for developing severe LRT infections include prematurity, pulmonary or cardiac disease, compromised immunity, and old age (4) . Current treatment options are limited, although a monoclonal antibody directed against the fusion (F) glycoprotein has been developed for prophylactic use (5) . Despite significant efforts in vaccine development over the past 50 years, no HRSV vaccines are currently licensed (6) . Limited availability of natural animal models of disease adds to the challenge of developing vaccines and antivirals.
HRSV is a member of the family Paramyxoviridae, subfamily Pneumovirinae, genus Pneumovirus (1) . It is an enveloped virus with a negative-sense, single-stranded RNA genome containing 10 transcription units. The glyco-(G) proteins facilitate virus attachment and entry (1, 7) , and the F glycoprotein is an important target of virus neutralizing antibodies (8) . Molecular epidemiological studies have identified two HRSV subgroups (A and B), which cause indistinguishable disease and cocirculate during, or alternate between, yearly outbreaks (9, 10) .
An improved understanding of HRSV pathogenesis would facilitate the development of novel intervention strategies. This requires virulent, well-characterized virus strains of known provenance, which can be evaluated in disease-relevant in vitro and in vivo model systems. Well-differentiated (wd) normal human bronchial epithelial (wd-NHBE) cultures grown at airliquid interface (ALI) have been identified as a useful in vitro model for HRSV as they contain ciliated cells which are natural HRSV targets (11) (12) (13) . Such cells provide a valuable bridge from in vitro to in vivo studies. Cotton rats represent a highly susceptible small-animal model for HRSV pathogenesis studies (14) . Recently, adult human volunteers were infected with wild-type A strains to assess the effectiveness of HRSV antivirals (15) (16) (17) . Irrespective of the approach used, it is critical to use naturally circulating viruses to ensure that study outcomes can be correlated with clinical outcomes. A long-standing challenge in virology is that clinical isolates often fail to cause overt cytopathic effect (CPE) in primary cells and in vivo; thus, infected cells must be stained to monitor the infection. This is challenging in vitro and magnified in vivo when low numbers of infected cells are present in tissues, which must be examined using ultrathin sections. These challenges have been addressed by generating recombinant (r) viruses from clinical samples and engineering them to express fluorescent proteins from an additional transcription unit (ATU), permitting novel insights into viral pathogenesis and targeted pathological assessment in appropriate cell lines and animal models (18) . To extend these studies, we obtained the genome sequence of HRSV B05 , a wildtype subgroup B strain. Assembly of a full-length molecular clone allowed the recovery of recombinant HRSV B05 (rHRSV B05 ) and insertion of an ATU containing the enhanced green fluorescent protein (EGFP) open reading frame (ORF) at position 5 between the phosphoprotein (P) and matrix (M) genes led to the generation of rHRSV B05 EGFP (5) . We characterized rHRSV B05 and rHRSV B05 EGFP(5) in vitro and show that it is virulent in vivo.
MATERIALS AND METHODS
Determination of a complete HRSV subtype B genomic sequence directly from clinical material. Deidentified clinical material was kindly provided by Peter Coyle (Royal Victoria Hospital, Belfast, Northern Ireland). The sample was obtained from a tracheal rinse of an HRSV-positive infant during the 2004-2005 HRSV season (HRSV B05 ). Total RNA was extracted from clinical material (500 l) using TRIzol LS reagent (Life Technologies). First-strand cDNA was generated using a SuperScript III first-strand synthesis system (Life Technologies) and negative-sense genespecific primers based on conserved regions of the HRSV subtype B genome. PCR primers were designed to amplify the complete viral genome in six overlapping fragments. PCR was performed on the cDNA using Phusion High-Fidelity DNA Polymerase (New England BioLabs). PCR products were purified using a QIAquick PCR purification kit (Qiagen) and sequenced using primers spanning the viral genome. Sequences were assembled, and a consensus was determined using Lasergene, version 10 (DNASTAR). Primer sequences are available on request. rgRSV is a recombinant virus based on HRSV strain A2 (HRSV A2 ), which expresses GFP from an ATU present at position 1 (promoter proximal of the genome (19) .
Construction of rHRSV B05 minigenomic and antigenomic plasmids. An HRSV minigenome plasmid, p(Ϫ)HRSV B05 DI-EGFP, contained an EGFP open reading frame (ORF) flanked by the viral 3= and 5= termini and preceded upstream by a T7 promoter, guanine trinucleotide, and ribozyme and followed downstream by a hepatitis delta virus ribozyme and T7 terminator sequences. A negative-sense viral RNA was produced upon transcription by T7 RNA polymerase. The minigenome construct was synthesized by GeneArt Gene Synthesis (Life Technologies) and ligated into a modified pBluescript vector (20) . HRSV N, P, M2-1, and L expression plasmids were constructed in pCG(MPBS) (21) . A full-length, antigenomic HRSV plasmid, pHRSV B05 , was constructed following restriction enzyme digestion and sequential ligation into the modified pBluescript vector (20) . The viral genome sequence was orientated with respect to the T7 promoter to produce an antigenomic RNA upon transcription. The full-length HRSV plasmid was modified to contain an ATU encoding EGFP located between the P and M genes, pHRSV B05 EGFP (5) .
Development of a minigenome assay and recovery of rHRSV. Confluent HEp-2 cells (ATCC, CCL-23) were infected with recombinant vaccinia virus MVA-T7 for 1 h at 37°C. Inoculum was aspirated, and Lipofectamine 2000 (Life Technologies) was used to transfect plasmid mixtures containing N, P, M2-1, L, and full-length or minigenome constructs. After 18 h the transfection mix was removed and replaced with OptiMEM (2 ml) (Life Technologies) containing 2% (vol/vol) fetal bovine serum (FBS). Cells were incubated for up to 7 days at 37°C with 5% (vol/vol) CO 2 . Supernatants from cells transfected with full-length constructs were used to infect fresh HEp-2 monolayers, and the presence of virus was confirmed by immuno-plaque assay, fluorescence, or CPE observed by phase-contrast microscopy. Cells, transfected with the HRSV minigenome construct, were observed daily by fluorescence microscopy to detect EGFP expression. Virus stocks were prepared in HEp-2 cells. Virus titers were determined by endpoint titration in HEp-2 cells.
In vitro infection assays and virus characterization. Growth kinetics was assessed by infection of HEp-2 cells at a multiplicity of infection (MOI) of 0.1. Triplicate samples were scraped, sonicated, and centrifuged to remove cellular fragments; the supernatant was snap-frozen as cell-free virus stock. Virus present in the sample for each time point was determined by endpoint titration in HEp-2 cells. Titers are expressed as 50% tissue culture infectious doses (TCID 50 ) calculated by the Reed and Muench method (22) . To determine glycosaminoglycan (GAG) indices, CHO cells expressing GAG or GAG-deficient cells were infected and analyzed by flow cytometry (23) . wd-NHBE cells were cultured in 12-mm/0.4-m-pore-size inserts (Corning) at ALI (24) . The apical surfaces of cells (estimated to contain 10 5 cells exposed at the surface) were infected at 25 to 26 days after growth at ALI. After 1 h of incubation at 37°C, inoculum was removed, and the apical surfaces were washed three times with Dulbecco's phosphate-buffered saline (DPBS) (500 l). At 2 days postinfection (d.p.i.), DPBS (500 l) was added to the apical compartment, and the cells were incubated at 37°C. After 10 min the DPBS and growth medium were harvested from the apical and basolateral compartments, respectively, for virus isolations and quantitative PCR (qPCR). Subsequently, automated wholewell scans were made by confocal laser scanning microscopy (CLSM) with an LSM700 system fitted on an Axio Observer Z1 inverted microscope (Zeiss), followed by semiautomated enumeration of EGFP-positive (EGFP ϩ ) cells (DotCount; MIT, Boston, MA). Viruses were titrated in HEp-2 cells using 10-fold (growth kinetics) or 3-fold (apical rinse) dilutions in flat-bottom 96-well plates and cultured for 5 to 7 days at 37°C. The presence of HRSV genomes in samples was determined by TaqMan reverse transcription-PCR (RT-PCR) as previously described (25) with slight modifications. A quantified positive control for HRSV B (Vircell) was added to express the results in genome equivalents. The cycle threshold (C T ) value was calculated automatically when the fluorophore signal (6-carboxyfluorescein [FAM] for HRSV A and tetramethylrhodamine [TAMRA] for HRSV B) was detected above the background level and was used to give a quantitative indication of viral copy numbers. All in vitro experiments were performed at least three times. Statistical analyses were performed with SPSS, version 20.0.
HRSV immuno-plaque assay. Serial 10-fold dilutions of HRSV were prepared in OptiMEM. Confluent HEp-2 cells cultured in 24-well plates were infected with each dilution (200 l) for 1 h at 37°C. Inoculum was aspirated, and 0.8% carboxy-methylcellulose (2 ml) (Sigma), in OptiMEM containing 2% (vol/vol) FBS, was added. Overlay medium was removed at 4 to 5 d.p.i., and cells were fixed in cold 80% (vol/vol) methanol for 1 h at 4°C. Plates were washed in distilled water and blocked with 5% (wt/vol) milk for 30 min. Goat anti-HRSV (Ab20745-1; Abcam) diluted 1:100 in blocking solution (200 l) was added. Following 1 h of incubation at room temperature with rocking, plates were washed in distilled water, and rabbit anti-goat horseradish peroxidase (HRP) conjugate (Ab6741; Abcam) diluted 1:100 in blocking solution (200 l) was added. Following 1 h of incubation at room temperature, plates were rinsed, and binding of the HRP-conjugated antibody was detected using 4-chloro-1-naphthol (200 l), which was converted to produce a gray/black pigment (Pierce).
In vivo infection experiment. Six groups of six female, 3-to 4-weekold cotton rats were infected intranasally with 10 4 TCID 50 of rHRSV in an inoculum volume of 10 l or 100 l to target the URT or LRT predominantly (26) . Animals (n ϭ 3/group) were euthanized by exsanguination at 4 or 6 d.p.i. The right lung was inflated with 2% (wt/ vol) agarose (Sigma-Aldrich), sliced, and submerged in medium (27) . Postmortem nasopharyngeal washings were collected, and the left lung was prepared for qPCR. Nasal concha, nasal septum, and agaroseinflated right lung (27) were screened and scored for microscopic fluorescence (AxioVert 25; Zeiss). Mann-Whitney U tests were used to compare differences between groups, and a P value of Յ0.05 was considered statistically significant.
Immunohistochemical (IHC) analysis of formalin-fixed tissues. Paraffin-embedded tissues were processed as previously described (28) . HRSV-infected cells were detected using a polyclonal rabbit antibody to EGFP (Invitrogen). All fluorescently stained slides were assessed, and digital fluorescent images were acquired with a Leica DF digital camera using Leica FW4000 software.
Confocal laser scanning microscopy. Nasal tissues and agarose-inflated lung slices were fixed with phosphate-buffered saline (PBS) containing 4% (wt/vol) paraformaldehyde, permeabilized with PBS containing 0.1% (vol/vol) Triton X-100 for 30 min, counterstained with the farred nuclear counterstain TO-PRO3 (Invitrogen) or 4=,6=-diamidino-2phenylindole (DAPI; Vectashield), and directly analyzed for EGFP fluorescence by an LSM700 system (Zeiss) or Leica SP5 microscope (Leica Microsystems). Three-dimensional (3D) images and movies were generated using Zen (Zeiss) or LCS (Leica) software.
Nucleotide sequence accession number. The complete genome sequence of HRSV B05 is available from GenBank under accession number KF640637.
RESULTS
Generation of a wild-type, subgroup B BA rHRSV. Total RNA was extracted directly from a tracheal rinse sample obtained from an infant infected with HRSV, and high-fidelity RT-PCR and rapid amplification of cDNA ends (RACE) were used to generate amplicons using previously described methods (29) . The consensus genome sequence indicated that the virus belonged to the Buenos Aires (BA) genotype of HRSV subgroup B. This genotype was first detected in Argentina in 1999 and is characterized by a 60nucleotide duplication in the G gene (30) . Viruses of the BA genotype have become the dominant global HRSV subtype B genotype (31, 32) , although why this is the case is unclear. Eukaryotic expression plasmids encoding HRSV B05 nucleocapsid (N), phospho-(P), and M2-1 and large (L) proteins and a negative-sense minigenome (HRSV B05 DI-EGFP) were constructed (Fig. 1A) , and a replication/transcription assay was established to optimize the conditions required to generate rHRSV B05 . Most negative-strand reverse genetics systems utilize T7 RNA polymerase to generate a full-length viral antigenomic RNA. Since T7 RNA polymerase initiates most efficiently on a stretch of guanine residues, efficient rHRSV A2 rescue has previously been achieved by inserting three guanine nucleotides between the T7 promoter and the HRSV leader (Le) sequence (33) (34) (35) . However, it is not clear whether this sequence is copied during viral replication. To negate this possibility, a hammerhead ribozyme (36) was inserted after the T7 promoter and three guanine nucleotides, which, along with the hepatitis delta ribozyme at the other end of the minigenome, allowed posttranscriptional cleavage to generate precise, authentic trailer (Tr) and Le termini at the ends of the minigenome (Fig. 1A) . EGFP ϩ cells were observed following transfection of the five plasmids into HEp-2 cells, indicating that the genomic termini and helper plasmids were functional (Fig. 1B) . No EGFP-positive cells were observed when the L protein expression plasmid was omitted (Fig. 1B, ϪL) , indicating that EGFP expression was driven exclusively by the viral RNA-dependent RNA polymerase (Fig. 1B) . Based on these findings a positive-sense full-length genome plasmid (pHRSV B05 ) was constructed, and rHRSV B05 was recovered following transfection into HEp-2 cells (Fig. 1C ). Importantly, it was not necessary to mutate nucleotide 4 of the Le sequence to achieve efficient rescue as has been described for rHRSV A2 (33, 37) , which demonstrates the biological importance of using authentic wild-type sequences. Full-genome consensus sequencing of the recombinant virus showed that no mutations had been introduced compared to the consensus sequence of the clinical specimen (data not shown). Indirect immunofluorescence ( Fig. 1D and E) and in situ plaque staining ( Fig. 1F and G) using an anti-HRSV F glycoprotein antibody permitted the detection of foci of infection. The fulllength HRSV plasmid was modified by insertion of an ATU encoding EGFP at position 5 in the genome (Fig. 1H) , and rHRSV B05 EGFP(5) was recovered ( Fig. 1I ). High levels of EGFP expression were obtained, and both single and fused infected cells were detected by UV microscopy (Fig. 1I) . Thus, an rHRSV B05 virus genetically identical to a clinical isolate was successfully generated that can be tracked in living cells in the absence of any overt CPE.
Growth characteristics of rHRSV B05 in transformed and primary human cells. HEp-2 cells were infected with rHRSV B05 or rHRSV B05 EGFP(5) at an equivalent multiplicity of infection (MOI). Both B05-based viruses displayed similar growth kinetics, reaching equivalent peak titers of 10 6 TCID 50 /ml (Fig. 1J ). It has been reported that HRSV strains differ in their binding affinity to glycosaminoglycan (GAG) moieties on the cell surface (19, 23) . Both rHRSV B05 and rHRSV B05 EGFP(5) displayed low GAG dependency indices (Fig. 1K) . In contrast, rgRSV had a high GAG dependency index.
Primary NHBE cells were differentiated at ALI to form polarized ciliated, nonciliated, basal, and goblet cells with functional tight junctions. These wd-NHBE cells were infected at an MOI of 0.01, 0.1, or 1, resulting in a dose-dependent number of infected cells 2 d.p.i. ( Fig. 2A ). Similar to previous observations with recombinant HRSV A2 strains in differentiated epithelial cells (12), CPE was not observed. Virus loads in apical rinses were determined both by virus isolation (Fig. 2B) and qPCR (Fig. 2C) . No reproducible differences in virus loads were determined between cultures infected with rHRSV B05 and rHRSV B05 EGFP (5) . Virus loads determined by qPCR showed a good correlation with the numbers of EGFP ϩ cells. Neither released virus nor virus genome was detected in the basolateral compartment (data not shown). This is consistent with the epitheliotropic nature of HRSV. rHRSV B05 efficiently infects cotton rats. Cotton rats were infected intranasally with 10 4 TCID 50 of rHRSV B05 or rHRSV B05 EGFP(5) in a low volume (10 l) to target the URT. Animals were sacrificed at 4 or 6 d.p.i., and unfixed respiratory tracts were screened by UV microscopy. High numbers of EGFP ϩ cells were detected at 4 d.p.i. in the nasal cavity of rHRSV B05 EGFP(5)-infected animals (Fig. 3A) . Discrete tracks of fluorescent cells were present in the epithelium of the nasal septum, reminiscent of what was previously observed in wd-NHBE cells (12) . No EGFP ϩ cells were detected microscopically in trachea or lungs. Pathological assessment and immunohistochemistry (IHC) in 7-m formalin-fixed lung sections indicated that both viruses predominantly infected ciliated respiratory epithelial cells (Fig. 3B ) and caused destruction of the epithelium (Fig. 3C) .
In order to target both the URT and LRT, cotton rats were intranasally infected with 10 4 TCID 50 in a larger volume (100 l) (26) . Macroscopically, fluorescence levels in the nasal concha and nasal septum were indistinguishable between animals infected with the low-or high-volume inoculum, and no EGFP ϩ cells were detected in the trachea. However, vastly different outcomes were observed when the lungs from infected animals were removed, inflated with agarose, sectioned, and screened for fluorescence. Infection with rHRSV B05 EGFP(5) resulted in high numbers of EGFP ϩ cells at 4 d.p.i. in the epithelium of the bronchi and bronchioles in the lung slices (Fig. 3D ). The number of EGFP ϩ cells in the LRT was lower at 6 d.p.i.
Virus loads were determined in nasal lavage samples ( Fig. 3E and F) and lung tissue ( Fig. 3G and H) by virus isolation (Fig. 3E and G) or qPCR ( Fig. 3F and H) for animals infected with a low (Fig. 3 , hatched columns) or high ( Fig. 3 , nonhatched columns) volume of intranasal inoculum. The results corroborated the macroscopic observations that high viral loads were detected in the URT of all animals ( Fig. 3E and F) while only in animals inoculated with a high volume were significant virus loads detected in the LRT (Fig. 3G and H) .
Detection of rHRSV B05 EGFP(5) in the respiratory tract by optical sectioning. The power of targeted pathology in understanding the spatial dynamics and pathological consequences of rHRSV B05 EGFP(5) infection is evident when standard IHC in 7-m formalin-fixed lung sections ( Fig. 4A and B) is compared with optical sectioning of living tissues immediately after necropsy ( Fig. 4C to G) . More infected cells were detected in agarose-inflated lung slices reconstructed in three dimensions using confocal laser scanning microscopy (CLSM) than by IHC, and sheets of infected luminal epithelial cells of bronchi and bronchioles were present (Fig. 4C ). Small numbers of individual cells in the parenchyma of the lung were also present (Fig. 4C, inset and asterisk) . These cells could not be phenotypically characterized by IHC due to the section size and lower level of sensitivity due to backgrounds. Optical sectioning also allows greater cellular resolution since EGFP floods the cytoplasm of the cell, meaning that fine processes and cell-to-cell contacts were readily visible ( Fig. 4D and E, arrow).
DISCUSSION
We have developed a reverse genetics system based on an HRSV subgroup B clinical isolate and generated rHRSVs with or without an additional transcription unit encoding EGFP to study viral pathogenesis in the cotton rat model. Use of rHRSV B05 EGFP(5) allowed sensitive detection of infected cells both in vitro and in vivo in the early stages of infection in the absence of CPE. HEp-2 cells were suitable for virus passage in vitro, and the genomes were genetically stable: after 10 serial passages in HEp-2 cells, consensus sequencing revealed no mutations. In addition, the growth kinetics of rHRSV B05 and rHRSV B05 EGFP(5) were comparable, suggesting that insertion of an ATU into the HRSV genome did not result in virus attenuation. Laboratory-adapted viruses generated by extensive passage through a variety of disease-relevant and -nonrelevant cells and tissues have traditionally been used to develop molecular clones (34, (38) (39) (40) .
HRSV spread in differentiated human airway epithelial (HAE) cells has been described as a "comet-like" spread, driven by the directionality of the beat of the cilia (12) . Equivalent "comets" were present in the nasal conchae of infected cotton rats, demonstrating that these are relevant in vivo and not an in vitro artifact. Such localized virus spread has significant implications for the development and delivery of HRSV antivirals. We used the model to mirror the 1 to 2% of human cases where virus triggers bronchiolitis or severe pneumonia by varying the inoculation volume to target mainly the URT or concurrently the URT and LRT. Interestingly, rHRSV B05 EGFP(5) predominantly infected cells throughout the main branches of the bronchial tree, resulting in illumination of the bronchial tree. This aspect of HRSV pathogenesis has not previously been recapitulated in an animal model of HRSV or, to the best of our knowledge, in animals infected with any virus. Preferential infection of bronchial and bronchiolar epithelial cells mirrors the natural target cells of HRSV in humans (41) . Moreover, at 4 d.p.i. rHRSV B05 EGFP(5) titers were similar to those obtained from patients or volunteers infected with HRSV (15, 16, 42) . This illustrates the strength of the cotton rat model and shows the power of targeted pathology using EGFP-expressing recombinant viruses, which is only feasible due to the possibility of identifying infected tissues for blocking and processing immediately after necropsy.
Whereas existing in vitro and in vivo models of HRSV have focused mainly on subgroup A viruses, our recombinant virus is based on a subgroup B strain (31) . Antigenic differences between the two subgroups of HRSV are predominantly mediated by the highly variable G gene (10) and might facilitate evasion of host immune responses (43) . Despite these differences, infections with HRSV of either subgroup cause indistinguishable disease (1) . Although outside the scope of understanding primary pathogenesis, this system should permit fitness experiments between viruses with and without the insertion in the G protein. This could explain why the BA viruses have outcompeted all other subgroup B HRSVs.
Reverse genetics of nonsegmented negative-strand RNA viruses has come a long way in the last 20 years following the recovery of rabies virus (44) . The challenges of generating recombinant viruses are far from trivial, and much has been achieved with the original rHRSV systems (19, 34) . Given the significant investment of time in establishing reverse genetics systems, there tends to be a large activation energy required to develop second-or thirdgeneration systems. This is particularly true for HRSV, and, although tractable second-generation systems have been developed (45, 46) , no group has successfully generated a virulent rHRSV fully reflecting the sequence of a current, clinically relevant, wild-type strain and studied primary pathogenesis in this key small-animal model. In addition, in vitro and in vivo models employing subgroup B HRSV strains have been scarce; these will be of crucial importance for preclinical testing of the effectiveness of new intervention strategies. It is vital to extend ongoing studies and move in the direction of reverse genetics systems based on clinical isolates grown in disease-relevant cells. Only then will it be possible to understand HRSV pathogenesis fully and systematically to test novel interventions. The recombinant B05 viruses will help in this endeavor, and these should be augmented by the establishment of equivalent systems for subgroup A clinical isolates.
